Gidden-8: Comprehensive Product Profile
Gidden-8, manufactured by Solvista Healthcare, is a specialized pharmaceutical formulation containing Betahistine Hydrochloride I.P. 8 mg. It is primarily indicated for the management of vestibular disorders, most notably Ménière’s disease, which is characterized by debilitating vertigo, tinnitus, and progressive hearing loss.
Therapeutic Classification and Mechanism of Action
Betahistine Hydrochloride is a histamine analogue. Unlike traditional antihistamines that can cause drowsiness, Betahistine works as a weak $H_1$ receptor agonist and a potent $H_3$ receptor antagonist.
The clinical efficacy of Gidden-8 is driven by two primary mechanisms:
- Inner Ear Microcirculation: By acting on $H_3$ receptors, it promotes the vasodilation of blood vessels in the inner ear (stria vascularis). This improves microcirculation and reduces endolymphatic pressure, addressing the “hydrops” (fluid buildup) associated with Ménière’s disease.
- Vestibular Compensation: It modulates the activity of vestibular nuclei in the central nervous system, helping the brain adapt to balance signals and accelerating recovery following vestibular loss.
Key Indications and Benefits
As highlighted in the Solvista Healthcare promotional material, Gidden-8 offers several clinical advantages:
- Effective Vertigo Management: It significantly reduces the frequency and severity of vertigo attacks, allowing patients to regain stability and confidence in their daily movements.
- Reduction of Dizziness Episodes: Beyond acute vertigo, it addresses general lightheadedness and “off-balance” sensations.
- Symptomatic Relief for Ménière’s Disease: It helps in managing the triad of symptoms—vertigo, tinnitus (ringing in the ears), and hearing impairment.
- Well-Tolerated Therapy: Compared to older vestibular suppressants, Betahistine has a favorable safety profile with minimal sedative effects, making it suitable for long-term maintenance therapy.
Quality Assurance and Manufacturing
Solvista Healthcare emphasizes a commitment to international standards. The product is backed by:
- WHO-GMP Certification: Ensuring that the drug is consistently produced and controlled according to World Health Organization quality standards.
- ISO Certified: Reflecting a standardized management system for quality and safety.
- Quality Manufacturing: Utilizing high-grade Betahistine Hydrochloride I.P. (Indian Pharmacopoeia) to ensure purity and potency.
Dosage and Administration
Gidden-8 is presented in a 10×15 tablet blister pack (150 tablets total).
- Standard Dosing: The typical starting dose for adults is often 8 mg to 16 mg three times daily. However, the exact dosage must be tailored by a healthcare professional based on the patient’s response.
- Administration: Tablets should be taken preferably with or after meals to minimize potential gastrointestinal upset.
Safety and Precautions
While generally well-tolerated, patients should be aware of the following:
- Contraindications: It should be avoided by individuals with pheochromocytoma (a rare tumor of the adrenal gland).
- Asthma and Peptic Ulcers: Patients with a history of bronchial asthma or peptic ulcers should be monitored closely, as histamine analogues may exacerbate these conditions.
- Side Effects: Potential side effects include mild gastric distress, nausea, or headaches, which often resolve with dose adjustment or taking the medication with food.
